Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.

• Tác giả: Nuria Marquez Almuina, Georgia Andrew, Sarah Burns, Jennifer Byrne, Paul Cahalin, Mike Dennis, Sylvie D Freeman, Amanda Gilkes, Robert K Hills, Richard Kelly, Steven Knapper, Lucy Marsh, Nicholas McCarthy, Priyanka Mehta, Marlen Metzner, Ulrik Malthe Overgaard, Nigel H Russell, Rob S Sellar, Abin Thomas, Ian Thomas, Paresh Vyas
• Ngôn ngữ: eng
• Ký hiệu phân loại: 133.59 Types or schools of astrology originating in or associated with a national group; originating in or associated with a specific religion
• Thông tin xuất bản: United States : Journal of clinical oncology : official journal of the American Society of Clinical Oncology , 2025
• Bộ sưu tập: NCBI
• ID: 59645

Tóm tắt

 PURPOSE: To evaluate the survival benefit of chemotherapy intensification in older patients with AML who have not achieved a measurable residual disease (MRD)-negative remission. METHODS: Five hundred twenty-three patients with AML (median age, 67 years
  range, 51-79) without a flow cytometric MRD-negative remission response after a first course of daunorubicin and AraC (DA
  including 165 not in remission) were randomly assigned between up to two further courses of DA or intensified chemotherapy-either fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin (FLAG-Ida) or DA with cladribine (DAC). RESULTS: Overall survival (OS) was not improved in the intensification arms (DAC CONCLUSION: In this study of older patients with AML considered fit and with evidence of residual disease after first induction, chemotherapy intensification improved survival. DAC intensification was better tolerated than FLAG-Ida.